| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.
|
Can J Cardiol
|
2006
|
3.20
|
|
2
|
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care.
|
Can J Cardiol
|
2011
|
1.78
|
|
3
|
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.
|
Can J Cardiol
|
2007
|
1.70
|
|
4
|
18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial.
|
J Nucl Med
|
2010
|
1.56
|
|
5
|
The effects of continuous positive airway pressure on myocardial energetics in patients with heart failure and obstructive sleep apnea.
|
J Am Coll Cardiol
|
2007
|
1.53
|
|
6
|
Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure.
|
Congest Heart Fail
|
2004
|
1.51
|
|
7
|
Frequency of peripartum cardiomyopathy.
|
Am J Cardiol
|
2006
|
1.46
|
|
8
|
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure.
|
Can J Cardiol
|
2012
|
1.44
|
|
9
|
Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.
|
Transplantation
|
2008
|
1.44
|
|
10
|
Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE".
|
Am J Hypertens
|
2010
|
1.43
|
|
11
|
The prevalence of cardiac risk factors in women 45 years of age or younger undergoing angiography for evaluation of undiagnosed chest pain.
|
Can J Cardiol
|
2002
|
1.40
|
|
12
|
Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial.
|
Can J Cardiol
|
2011
|
1.37
|
|
13
|
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.
|
Can J Cardiol
|
2008
|
1.15
|
|
14
|
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials.
|
Can J Cardiol
|
2009
|
1.04
|
|
15
|
The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs.
|
Can J Cardiol
|
2010
|
1.00
|
|
16
|
Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature.
|
Can J Cardiol
|
2007
|
0.97
|
|
17
|
Relationship between natriuretic peptides and inflammation: proteomic evidence obtained during acute cellular cardiac allograft rejection in humans.
|
J Heart Lung Transplant
|
2008
|
0.95
|
|
18
|
Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension.
|
Am J Cardiol
|
2012
|
0.91
|
|
19
|
Tricuspid valve chordal tissue in endomyocardial biopsy specimens of patients with significant tricuspid regurgitation.
|
J Heart Lung Transplant
|
2005
|
0.91
|
|
20
|
2001 Canadian Cardiovascular Society Consensus Conference on cardiac transplantation.
|
Can J Cardiol
|
2003
|
0.90
|
|
21
|
Physician specialty and quality of care for CHF: different patients or different patterns of practice?
|
Can J Cardiol
|
2003
|
0.90
|
|
22
|
BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure.
|
Congest Heart Fail
|
2005
|
0.87
|
|
23
|
Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure.
|
Congest Heart Fail
|
2012
|
0.87
|
|
24
|
Acute and chronic effects of continuous positive airway pressure therapy on left ventricular systolic and diastolic function in patients with obstructive sleep apnea and congestive heart failure.
|
Can J Cardiol
|
2008
|
0.87
|
|
25
|
Effect of Orlistat in obese patients with heart failure: a pilot study.
|
Congest Heart Fail
|
2005
|
0.87
|
|
26
|
Imaging the failing right ventricle.
|
Curr Opin Cardiol
|
2012
|
0.85
|
|
27
|
Cardiac allograft vasculopathy: pathology, prevention and treatment.
|
Curr Opin Cardiol
|
2006
|
0.85
|
|
28
|
Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
|
J Heart Lung Transplant
|
2011
|
0.84
|
|
29
|
Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value.
|
Can J Physiol Pharmacol
|
2011
|
0.84
|
|
30
|
Depression in heart failure.
|
Curr Opin Cardiol
|
2013
|
0.84
|
|
31
|
Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm.
|
Can J Cardiol
|
2004
|
0.84
|
|
32
|
The concept of ventricular reserve in heart failure and pulmonary hypertension: an old metric that brings us one step closer in our quest for prediction.
|
Curr Opin Cardiol
|
2011
|
0.84
|
|
33
|
Neuroendocrine profiling of humans receiving cardiac allografts.
|
J Heart Lung Transplant
|
2005
|
0.83
|
|
34
|
Relation between right ventricular function and increased right ventricular [18F]fluorodeoxyglucose accumulation in patients with heart failure.
|
Circ Cardiovasc Imaging
|
2010
|
0.83
|
|
35
|
Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation.
|
J Heart Lung Transplant
|
2008
|
0.83
|
|
36
|
Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study.
|
Transpl Int
|
2010
|
0.83
|
|
37
|
Mechanisms of functional mitral regurgitation in ischemic cardiomyopathy determined by transesophageal echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial).
|
Am J Cardiol
|
2013
|
0.83
|
|
38
|
Under-utilization of mechanical circulatory support in Canada: why and what can be done?
|
Artif Organs
|
2004
|
0.81
|
|
39
|
Enhanced external counterpulsation in ischemic heart disease and congestive heart failure.
|
CMAJ
|
2004
|
0.81
|
|
40
|
Sleep apnea in chronic heart failure.
|
Curr Opin Cardiol
|
2008
|
0.81
|
|
41
|
Persistent orthopnea and the prognosis of patients in the heart failure clinic.
|
Congest Heart Fail
|
2004
|
0.80
|
|
42
|
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
|
Cerebrovasc Dis
|
2013
|
0.80
|
|
43
|
Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial.
|
Trials
|
2013
|
0.80
|
|
44
|
The role of vitamin D in chronic heart failure.
|
Curr Opin Cardiol
|
2013
|
0.80
|
|
45
|
Do high doses of AT(1)-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure?
|
Clin Sci (Lond)
|
2013
|
0.80
|
|
46
|
Recent progress in the genetics of cardiomyopathy and its role in the clinical evaluation of patients with cardiomyopathy.
|
Curr Opin Cardiol
|
2011
|
0.80
|
|
47
|
Diagnosis of graft coronary artery disease.
|
Curr Opin Cardiol
|
2007
|
0.79
|
|
48
|
Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
|
J Heart Lung Transplant
|
2005
|
0.79
|
|
49
|
Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus.
|
Transplantation
|
2006
|
0.79
|
|
50
|
Is ventilatory efficiency (VE/VCO(2) slope) associated with right ventricular oxidative metabolism in patients with congestive heart failure?
|
Eur J Heart Fail
|
2008
|
0.79
|
|
51
|
An unusual case of hypertensive diastolic heart failure with bilateral subclavian artery stenosis.
|
Can J Cardiol
|
2009
|
0.78
|
|
52
|
Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
|
J Heart Lung Transplant
|
2008
|
0.78
|
|
53
|
Heart transplantation at the Ottawa heart institute: comparison with Canadian and international results.
|
Artif Organs
|
2004
|
0.78
|
|
54
|
Ventricular assist devices as a bridge to cardiac transplantation: the Ottawa experience.
|
Artif Organs
|
2004
|
0.77
|
|
55
|
Cellular transplantation: future therapeutic options.
|
Curr Opin Cardiol
|
2007
|
0.77
|
|
56
|
Thyrotoxicosis-an uncommon cause of heart failure.
|
Cardiovasc Pathol
|
2005
|
0.77
|
|
57
|
Cardiorenal syndrome and heart failure.
|
Curr Opin Cardiol
|
2010
|
0.77
|
|
58
|
Prevalence and clinical implications of anemia in congestive heart failure patients followed at a specialized heart function clinic.
|
Congest Heart Fail
|
2006
|
0.77
|
|
59
|
Images in cardiovascular medicine. Fluorine-18-labeled deoxyglucose positron emission tomography in the diagnosis and management of aortitis with pulmonary artery involvement.
|
Circulation
|
2005
|
0.77
|
|
60
|
New therapies in acute decompensated heart failure.
|
Curr Opin Cardiol
|
2008
|
0.77
|
|
61
|
Cardiac retransplantation: an ethical dilemma.
|
Curr Opin Cardiol
|
2006
|
0.76
|
|
62
|
Ultrafiltration in the management of acute decompensated heart failure.
|
Curr Opin Cardiol
|
2010
|
0.76
|
|
63
|
Cardiac signaling molecules and plasma biomarkers after cardiac transplantation: impact of tacrolimus versus cyclosporine.
|
J Heart Lung Transplant
|
2013
|
0.76
|
|
64
|
In vivo evaluation of the biocompatibility of the totally implantable ventricular assist device (HeartSaver VAD).
|
ASAIO J
|
2003
|
0.76
|
|
65
|
Cardiac transplantation in HIV-positive patients: are we there yet?
|
J Heart Lung Transplant
|
2007
|
0.75
|
|
66
|
Heart failure and sleep-disordered breathing.
|
Curr Opin Cardiol
|
2016
|
0.75
|
|
67
|
Chemotherapy-related cardiac dysfunction: grey area in type I and type II classification.
|
Curr Opin Cardiol
|
2016
|
0.75
|
|
68
|
The role of statins in chronic heart failure.
|
Curr Opin Cardiol
|
2009
|
0.75
|
|
69
|
Thermal therapy: a viable adjunct in the treatment of heart failure?
|
Congest Heart Fail
|
2008
|
0.75
|
|
70
|
Improved early survival with the total artificial heart.
|
Artif Organs
|
2004
|
0.75
|
|
71
|
[B-type natriuretic peptide and cardiovascular disease].
|
Arq Bras Cardiol
|
2003
|
0.75
|
|
72
|
Canadian Consensus on cardiac transplantation in pediatric and adult congenital heart disease patients 2004: executive summary.
|
Can J Cardiol
|
2005
|
0.75
|
|
73
|
The impact of obesity on heart failure.
|
Curr Opin Cardiol
|
2017
|
0.75
|
|
74
|
Heart rate and heart failure.
|
Curr Opin Cardiol
|
2016
|
0.75
|
|
75
|
Genetic testing in cardiomyopathies: an update on indications and benefits.
|
Curr Opin Cardiol
|
2016
|
0.75
|
|
76
|
An update in the management of acute decompensated heart failure.
|
Curr Opin Cardiol
|
2014
|
0.75
|
|
77
|
Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
|
Curr Opin Cardiol
|
2007
|
0.75
|